6-[1-phenylpyrazol-4-yl]-1-cyclobutyl-3-(pyrid-4-ylmethyl)-5-nitro-1,3-dihydropyrimidine-2,4-dione | 1044663-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 6-[1-phenylpyrazol-4-yl]-1-cyclobutyl-3-(pyrid-4-ylmethyl)-5-nitro-1,3-dihydropyrimidine-2,4-dione
• 英文别名: 1-Cyclobutyl-5-nitro-6-(1-phenylpyrazol-4-yl)-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione
• CAS: 1044663-18-4
• 化学式: C₂₃H₂₀N₆O₄
• 分子量: 444.45
• InChiKey: PHZJKJJNGFVIRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• A2B adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050119287A1

  公开（公告）日：2005-06-02

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists having the following structure: wherein R 1 and R 2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R 4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.

  本发明涉及一种新的化合物，该化合物是A2B腺苷受体拮抗剂，其结构如下：其中R1和R2独立地选择自氢、可选择性取代的烷基、可选择性取代的环烷基、可选择性取代的芳基和可选择性取代的杂环芳基，而R4是可选择性取代的杂环芳基基团。本发明的化合物可用于治疗各种疾病状态，包括哮喘、慢性阻塞性肺疾病、肺部炎症、肺气肿、糖尿病性疾病、炎症性胃肠道疾病、免疫/炎症性疾病、心血管疾病、神经系统疾病和与血管生成相关的疾病。
• A2B ADENOSINE RECEPTOR ANTAGONISTS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1678181A2

  公开（公告）日：2006-07-12
• US7449473B2
  申请人：——

  公开号：US7449473B2

  公开（公告）日：2008-11-11
• [EN] A2B ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE A2B
  申请人：CV THERAPEUTICS INC

  公开号：WO2005042534A2

  公开（公告）日：2005-05-12

  Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure (I) wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.